publication date: Jul. 14, 2017
Drugs and Targets FDA converts accelerated approval of Amgen’s Blincyto to full approval in ALL
FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) to include overall survival data from the phase III TOWER study.
The approval converts Blincyto’s accelerated approval to a full approval. The sBLA approval also included data from the phase II ALCANTARA study supporting the treatment of patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The approval expands the indication of Blincyto for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.
“For researchers and physicians, overall survival is the primary goal of treatment and the gold standard of outcomes, demonstrating a clear value to patients,” said Anthony Stein, study investigator and co-director of the Gehr Family Center for Leukemia Research, City of Hope. “Data from the TOWER study support the use of this single agent bispecific T cell engager immunotherapy, the first to demonstrate superior overall survival in patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL, offering a much needed alternative with significantly improved outcomes over standard of care chemotherapy.”
BLINCYTO, the first single-agent immunotherapy to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL, was previously granted breakthrough therapy designation and accelerated approval.
It is also … Continue reading FDA converts accelerated approval of Amgen’s Blincyto to full approval in ALL
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.